Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting

Reuters

2025/05/29

Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting

Sino Biopharmaceutical Limited has announced promising data from a Phase II clinical study of TQB2868, a PD-1/TGF-β bi-functional fusion protein, combined with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study enrolled 40 stage IV mPDAC patients, with 36 being evaluable. The preliminary results demonstrated robust efficacy, marking a significant breakthrough in addressing the treatment challenges of pancreatic cancer, known for its high malignancy and low survival rate. The company is currently in discussions with China's National Medical Products Administration to advance to Phase III trials, with the potential for TQB2868 to become the first immune checkpoint inhibitor as a first-line treatment option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539250463"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539250463\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539250463?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539250463","market":"us","top_or_hot":-1,"title":"Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sino Biopharmaceutical Limited has announced promising data from a Phase II clinical study of TQB2868, a PD-1/TGF-β bi-functional fusion protein, combined with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study enrolled 40 stage IV mPDAC patients, with 36 being evaluable. The preliminary results demonstrated robust efficacy, marking a significant breakthrough in addressing the treatment challenges of pancreatic cancer, known for its high malignancy and low survival rate. The company is currently in discussions with China's National Medical Products Administration to advance to Phase III trials, with the potential for TQB2868 to become the first immune checkpoint inhibitor as a first-line treatment option.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-29 20:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sino Biopharmaceutical Limited has announced promising data from a Phase II clinical study of TQB2868, a PD-1/TGF-β bi-functional fusion protein, combined with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study enrolled 40 stage IV mPDAC patients, with 36 being evaluable. The preliminary results demonstrated robust efficacy, marking a significant breakthrough in addressing the treatment challenges of pancreatic cancer, known for its high malignancy and low survival rate. The company is currently in discussions with China's National Medical Products Administration to advance to Phase III trials, with the potential for TQB2868 to become the first immune checkpoint inhibitor as a first-line treatment option.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中國生物製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLbJ1hqs:1","article_id":"2539250463","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539250463","pubTimestamp":1748521386,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1515":"抗疫概念","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1589":"北水核心资产","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC"},"translate_title":"中国生物制药有限公司在2025年ASCO会议上展示TQB2868治疗转移性胰腺癌的有希望的II期研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"Sino Biopharmaceutical Limited Presents Promising Phase II Study Results for TQB2868 in Treating Metastatic Pancreatic Cancer at 2025 ASCO Meeting\n    \n\n        Sino Biopharmaceutical Limited has announced promising data from a Phase II clinical study of TQB2868, a PD-1/TGF-β bi-functional fusion protein, combined with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study enrolled 40 stage IV mPDAC patients, with 36 being evaluable. The preliminary results demonstrated robust efficacy, marking a significant breakthrough in addressing the treatment challenges of pancreatic cancer, known for its high malignancy and low survival rate. The company is currently in discussions with China's National Medical Products Administration to advance to Phase III trials, with the potential for TQB2868 to become the first immune checkpoint inhibitor as a first-line treatment option.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}